IGCS 2022

International Gynecologic Cancer Society Global Meeting 2022

29 Sep–01 October 2022 | New York City

IGCS 2022 will provide you with the opportunity to learn about the latest clinical advances as well as international developments in research, practice, and treatment for the holistic care of women with gynecological cancer.

Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary

Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovary

Lilian T. Gien • 3 Oct 2022

Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary

Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary

Lilian T. Gien • 3 Oct 2022

Outcomes of gynecological cancer surgery during the COVID-19 pandemic

Outcomes of gynecological cancer surgery during the COVID-19 pandemic

Elaine Leung • 30 Sep 2022

Learnings from COVID-19 on the surgical management of gynecological cancer patients

Learnings from COVID-19 on the surgical management of gynecological cancer patients

Elaine Leung • 30 Sep 2022

Research allocation and international collaboration

Research allocation and international collaboration

Elaine Leung • 30 Sep 2022

Highlights from IGCS 2022

Highlights from IGCS 2022

Elaine Leung • 30 Sep 2022

Optimal management of recurrent low grade endometrial cancer

Optimal management of recurrent low grade endometrial cancer

Mansoor Mirza • 29 Sep 2022

Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer

Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer

Mansoor Mirza • 29 Sep 2022